XJPX4263
Market cap67mUSD
Jan 23, Last price
636.00JPY
1D
-0.78%
1Q
13.98%
IPO
-60.25%
Name
Susmed Inc
Chart & Performance
P/E
—
P/S
30.66
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
343m
-35.44%
Net income
-357m
L+604.28%
CFO
-231m
L
Profile
SUSMED,Inc. develops and sells therapeutic applications in Japan. It develops smartphone based digital therapeutics applications for diseases with insomnia, breast cancer, and kidney disease. The company also develops and sells development platform for therapeutic apps and clinical trial systems. In addition, it offers medical data analysis and consulting services. The company was incorporated in 2015 and is headquartered in Tokyo, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | |
| Income | |||||
Revenues | 342,577 -35.44% | 530,654 67.47% | 316,873 174.38% | ||
Cost of revenue | 707,557 | 578,970 | 546,025 | ||
Unusual Expense (Income) | |||||
NOPBT | (364,980) | (48,316) | (229,152) | ||
NOPBT Margin | |||||
Operating Taxes | 1,210 | 1,210 | 319 | ||
Tax Rate | |||||
NOPAT | (366,190) | (49,526) | (229,471) | ||
Net income | (357,415) 604.28% | (50,749) -78.26% | (233,483) -15.88% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 37,373 | 61,562 | 3,481,986 | ||
BB yield | -0.37% | -0.21% | -26.12% | ||
| Debt | |||||
Debt current | |||||
Long-term debt | |||||
Deferred revenue | |||||
Other long-term liabilities | 6,390 | 5,650 | 5,650 | ||
Net debt | (4,871,920) | (5,056,838) | (4,912,074) | ||
| Cash flow | |||||
Cash from operating activities | (230,762) | 100,591 | (165,283) | ||
CAPEX | (9,277) | (18,189) | (12,612) | ||
Cash from investing activities | (8,528) | (18,189) | (20,362) | ||
Cash from financing activities | 37,372 | 62,362 | 3,463,075 | ||
FCF | (366,190) | (49,526) | (229,471) | ||
| Balance | |||||
Cash | 4,846,920 | 5,048,838 | 4,904,074 | ||
Long term investments | 25,000 | 8,000 | 8,000 | ||
Excess cash | 4,854,791 | 5,030,305 | 4,896,230 | ||
Stockholders' equity | (818,875) | (512,656) | 1,341,250 | ||
Invested Capital | 5,429,562 | 5,360,134 | 3,475,804 | ||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 16,693 | 16,402 | 14,683 | ||
Price | 600.00 -66.37% | 1,784.00 96.48% | 908.00 | ||
Market cap | 10,015,744 -65.77% | 29,261,530 119.48% | 13,332,346 | ||
EV | 5,143,824 | 24,204,692 | 8,421,272 | ||
EBITDA | (358,993) | (42,768) | (227,103) | ||
EV/EBITDA | |||||
Interest | |||||
Interest/NOPBT | |||||